Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich's Ascites Carcinoma: Role of Angiotensin (1–7)

Local renin-angiotensin systems exist in various malignant tumor tissues; this suggests that the main effector peptide, angiotensin II, could act as a key factor in tumor growth. The underlying mechanisms for the anti-angiogenic effect of angiotensin II type 1 receptor blockers need to be further evaluated. The present study was carried out to investigate the anti-angiogenic effect of olmesartan alone or in combination with sorafenib, an angiotensin (1–7) agonist or an angiotensin (1–7) antagonist in Ehrlich's ascites carcinoma-bearing mice. The tumor was induced by intradermal injection of Ehrlich's ascites carcinoma cells into mice. Tumor discs were used to evaluate the microvessel density; the serum levels of vascular endothelial growth factor (VEGF) and serum insulin-like growth factor I (IGF-I); and their intratumoral receptors, VEGF receptor-2 and IGF-I receptor, respectively. All parameters were determined following the treatment course, which lasted for 21 days post-inoculation. Monotherapy with olmesartan and its combination with sorafenib resulted in a significant reduction in microvessel density and serum levels of VEGF and IGF-I, as well as their intratumoral receptors. In addition, the combination of olmesartan (30 mg/kg) with an angiotensin (1–7) agonist reduced the microvessel density, IGF-I serum levels and the levels of its intratumoral receptor. In conclusion, olmesartan reduced the levels of the angiogenesis markers IGF-I and VEGF and down-regulated the intratumoral expression of their receptors in a dose-dependent manner, and these effects were dependent on the angiotensin (1–7) receptor. These results suggest that olmesartan is a promising adjuvant to sorafenib in the treatment of cancer.

[1]  A. Miyajima,et al.  Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. , 2002, Cancer research.

[2]  O. Wolkenhauer,et al.  The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells , 2010, BMC Cancer.

[3]  Andrew W Roddam,et al.  Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies , 2010, The Lancet. Oncology.

[4]  E. Krieger,et al.  State-of-the-Art lecture: influence of exercise training on neurogenic control of blood pressure in spontaneously hypertensive rats. , 1999, Hypertension.

[5]  D. Sica.  Angiogenesis inhibitors and hypertension: an emerging issue. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Harris,et al.  Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. , 2000, Cancer research.

[7]  H. Huynh,et al.  Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor , 2009, Molecular Cancer Therapeutics.

[8]  Ê. Ferreira,et al.  Ehrlich tumor as model to study artificial hyperthyroidism influence on breast cancer. , 2007, Pathology, research and practice.

[9]  Shokei Kim,et al.  Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. , 2000, Pharmacological reviews.

[10]  Y. Aggour,et al.  Downregulation of transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF) in ehrlich ascites carcinoma-bearing mice using stearic acid-grafted carboxymethyl chitosan (SA-CMC) , 2012 .

[11]  D. Soto-Pantoja,et al.  Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor , 2009, Molecular Cancer Therapeutics.

[12]  D. Hanahan,et al.  Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. , 1999, Cancer research.

[13]  J. Cline,et al.  Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. , 2007, Cancer research.

[14]  M. AL Abdan.  Alfa-Lipoic Acid Controls Tumor Growth and Modulates Hepatic Redox State in Ehrlich-Ascites-Carcinoma-Bearing Mice , 2012, TheScientificWorldJournal.

[15]  Jaclyn H Neo,et al.  The renin-angiotensin system and malignancy. , 2008, Carcinogenesis.

[16]  H. Dvorak,et al.  VEGF-A and the induction of pathological angiogenesis. , 2007, Annual review of pathology.

[17]  D. Diz,et al.  Antiproliferative Actions of Angiotensin-(1-7) in Vascular Smooth Muscle , 1999 .

[18]  D. Diz,et al.  State-of-the-Art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. , 1999, Hypertension.

[19]  N. Alenina,et al.  An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect , 2011, Clinics.

[20]  Qiqin Yin-Goen,et al.  Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression , 2005, Modern Pathology.

[21]  E. Kikuchi,et al.  Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer , 2007, The Prostate.

[22]  Kuen-Feng Chen,et al.  Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells , 2013, Breast Cancer Research.

[23]  D. Diz,et al.  Counterregulatory actions of angiotensin-(1-7). , 1997, Hypertension.

[24]  B. Lévy,et al.  Angiotensin II Angiogenic Effect In Vivo Involves Vascular Endothelial Growth Factor- and Inflammation-Related Pathways , 2002, Laboratory Investigation.

[25]  K. Chayama,et al.  Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist , 2001, FEBS letters.

[26]  F. Rahbari-Oskoui.  Angiotensin II receptor blockers and risk of cancer: cause for concern? , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  J. Catravas,et al.  Sequential development of angiotensin receptors and angiotensin I converting enzyme during angiogenesis in the rat subcutaneous sponge granuloma , 1997, British journal of pharmacology.

[28]  A. Greene,et al.  Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. , 1996, Hypertension.

[29]  E. Kikuchi,et al.  Angiotensin II Type 1 Receptor Antagonist Candesartan as an Angiogenic Inhibitor in a Xenograft Model of Bladder Cancer , 2006, Clinical Cancer Research.

[30]  M. Clark,et al.  Molecular Mechanisms of Inhibition of Vascular Growth by Angiotensin-(1-7) , 2003, Hypertension.

[31]  D. Averill,et al.  Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. , 2005, Kidney international.

[32]  S. Zaitone,et al.  Rosuvastatin promotes angiogenesis and reverses isoproterenol-induced acute myocardial infarction in rats: role of iNOS and VEGF. , 2012, European journal of pharmacology.

[33]  R. Touyz,et al.  Recent advances in angiotensin II signaling. , 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[34]  Francesco Hofmann,et al.  Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. , 2005, Drug discovery today.

[35]  Jian-Mei Li,et al.  Inhibitory Effects of AT1 Receptor Blocker, Olmesartan, and Estrogen on Atherosclerosis Via Anti-Oxidative Stress , 2005, Hypertension.

[36]  Yi Sun,et al.  Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. , 2002, Current cancer drug targets.

[37]  K. Jacobson,et al.  Angiotensin II-induced apoptosis in rat cardiomyocyte culture: a possible role of AT1 and AT2 receptors , 2001, Journal of hypertension.

[38]  K. Dux,et al.  Of ehrlich ascites carcinoma. , 1967 .

[39]  T. Choueiri,et al.  Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. , 2011, Critical reviews in oncology/hematology.

[40]  J. Totoń-Żurańska,et al.  Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice , 2012, Pharmacological Reports.

[41]  R. Santos,et al.  Angiotensin-(1-7): beyond the cardio-renal actions. , 2013, Clinical science.

[42]  G. Rosner,et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  W. Jia,et al.  Expression and Correlation of Hypoxia-inducible Factor-1α, Vascular Endothelial Growth Factor and Microvessel Density in Experimental Rat Hepatocarcinogenesis , 2009, The Journal of international medical research.

[44]  Wei Huang,et al.  Angiotensin II Type 1 Receptor Antagonist Suppress Angiogenesis and Growth of Gastric Cancer Xenografts , 2008, Digestive Diseases and Sciences.

[45]  P. Hoff,et al.  Role of angiogenesis in the pathogenesis of cancer. , 2012, Cancer treatment reviews.

[46]  V. Kosma,et al.  Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy. , 2010, European journal of cancer.

[47]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[48]  A. Ross,et al.  Sorafenib exerts anti-glioma activity in vitro and in vivo , 2010, Neuroscience Letters.

[49]  C. Brown,et al.  Angiotensin II type 1 receptor expression in human breast tissues. , 1997, British Journal of Cancer.

[50]  M. Itoman,et al.  Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. , 2002, Biochemical and biophysical research communications.

[51]  Y. Moustafa,et al.  Anti-angiogenic effect of resveratrol or curcumin in Ehrlich ascites carcinoma-bearing mice. , 2011, European journal of pharmacology.

[52]  G. D. Cassali,et al.  Efeito do hipotireoidismo no tumor de Ehrlich sólido em camundongos fêmeas castradas e não castradas , 2004 .

[53]  Mathias Hoehn,et al.  In-Vivo Visualization of Tumor Microvessel Density and Response to Anti-Angiogenic Treatment by High Resolution MRI in Mice , 2011, PloS one.

[54]  L. Ellis,et al.  Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  Y. Kubota,et al.  Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer , 2005, International Journal of Clinical Oncology.

[56]  Y. Kawahito,et al.  Telmisartan is a potent target for prevention and treatment in human prostate cancer. , 2008, Oncology reports.

[57]  I. Haznedaroglu,et al.  Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. , 2002, Medical hypotheses.

[58]  M. Hamada,et al.  An angiotensin II type 1 receptor blocker, candesartan, increases myocardial apoptosis in rats with acute ischemia-reperfusion. , 2001, Hypertension research : official journal of the Japanese Society of Hypertension.

[59]  N. Weidner,et al.  Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow , 1998, The Journal of pathology.

[60]  G. Gores,et al.  The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006 , 2005, Oncogene.

[61]  C. Chassagne,et al.  ANG II type 1 receptor antagonist irbesartan inhibits coronary angiogenesis stimulated by chronic intermittent hypoxia in neonatal rats. , 2007, American journal of physiology. Heart and circulatory physiology.

[62]  C. Yeo,et al.  Blocking Angiotensin II Type 1 Receptor Triggers Apoptotic Cell Death in Human Pancreatic Cancer Cells , 2010, Pancreas.